株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

心筋線維症:パイプライン製品分析

Myocardial Fibrosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 350076
出版日 ページ情報 英文 82 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
心筋線維症:パイプライン製品分析 Myocardial Fibrosis - Pipeline Review, H1 2016
出版日: 2016年06月08日 ページ情報: 英文 82 Pages
概要

心筋線維症は、心臓線維芽細胞の不適切な増殖によって心臓弁の異常肥大が起こる疾患です。その症状には、胸の痛み、腹部の膨満感、吐き気、疲労感などがあります。

当レポートでは、世界における心筋線維症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

心筋線維症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

心筋線維症:企業で開発中の治療薬

心筋線維症:大学/機関で研究中の治療薬

心筋線維症:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

心筋線維症:企業で開発中の製品

心筋線維症:大学/機関で研究中の製品

心筋線維症の治療薬開発に従事している企業

  • AstraZeneca Plc
  • BioLineRx, Ltd.
  • Digna Biotech, S.L.
  • Evotec AG
  • Galectin Therapeutics, Inc.
  • GTx, Inc.
  • MandalMed, Inc.
  • miRagen Therapeutics, Inc.
  • ProMetic Life Sciences Inc.
  • Virocan Therapeutics Private Limited

心筋線維症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

心筋線維症:最近のパイプライン動向

心筋線維症:休止中のプロジェクト

心筋線維症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8186IDB

Summary

Global Markets Direct's, 'Myocardial Fibrosis - Pipeline Review, H1 2016', provides an overview of the Myocardial Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis
  • The report reviews pipeline therapeutics for Myocardial Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Myocardial Fibrosis therapeutics and enlists all their major and minor projects
  • The report assesses Myocardial Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Myocardial Fibrosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Myocardial Fibrosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Myocardial Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Myocardial Fibrosis Overview
  • Therapeutics Development
    • Pipeline Products for Myocardial Fibrosis - Overview
    • Pipeline Products for Myocardial Fibrosis - Comparative Analysis
  • Myocardial Fibrosis - Therapeutics under Development by Companies
  • Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes
  • Myocardial Fibrosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Myocardial Fibrosis - Products under Development by Companies
  • Myocardial Fibrosis - Products under Investigation by Universities/Institutes
  • Myocardial Fibrosis - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Evotec AG
    • Galectin Therapeutics, Inc.
    • GTx, Inc.
    • Invivosciences, Inc.
    • MandalMed, Inc.
    • miRagen Therapeutics, Inc.
    • Regulus Therapeutics Inc.
    • Shire Plc
    • TRACON Pharmaceuticals, Inc.
  • Myocardial Fibrosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AZ-876 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Tissue Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GM-CT-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GRMD-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GTx-878 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-4220 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NM-922 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RG-012 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-627 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Soluble Epoxide Hydrolase for Myocardial Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SP-20102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TPI-2049 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRC-105 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRC-205 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Myocardial Fibrosis - Recent Pipeline Updates
  • Myocardial Fibrosis - Dormant Projects
  • Myocardial Fibrosis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Myocardial Fibrosis, H1 2016
  • Number of Products under Development for Myocardial Fibrosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Myocardial Fibrosis - Pipeline by AstraZeneca Plc, H1 2016
  • Myocardial Fibrosis - Pipeline by Evotec AG, H1 2016
  • Myocardial Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2016
  • Myocardial Fibrosis - Pipeline by GTx, Inc., H1 2016
  • Myocardial Fibrosis - Pipeline by Invivosciences, Inc., H1 2016
  • Myocardial Fibrosis - Pipeline by MandalMed, Inc., H1 2016
  • Myocardial Fibrosis - Pipeline by miRagen Therapeutics, Inc., H1 2016
  • Myocardial Fibrosis - Pipeline by Regulus Therapeutics Inc., H1 2016
  • Myocardial Fibrosis - Pipeline by Shire Plc, H1 2016
  • Myocardial Fibrosis - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Myocardial Fibrosis Therapeutics - Recent Pipeline Updates, H1 2016
  • Myocardial Fibrosis - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Myocardial Fibrosis, H1 2016
  • Number of Products under Development for Myocardial Fibrosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top